177 related articles for article (PubMed ID: 38126035)
1. Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors.
Bezu L; Kepp O; Kroemer G
Oncoimmunology; 2023; 12(1):2272352. PubMed ID: 38126035
[TBL] [Abstract][Full Text] [Related]
2. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
[TBL] [Abstract][Full Text] [Related]
3. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.
Arai H; Xiao Y; Loupakis F; Kawanishi N; Wang J; Battaglin F; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Falcone A; Millstein J; Lenz HJ
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172883
[TBL] [Abstract][Full Text] [Related]
5. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers.
Shi F; Huang X; Hong Z; Lu N; Huang X; Liu L; Liang T; Bai X
Cancer Lett; 2023 May; 562():216167. PubMed ID: 37031916
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.
Liu P; Chen J; Zhao L; Hollebecque A; Kepp O; Zitvogel L; Kroemer G
Oncoimmunology; 2022; 11(1):2093518. PubMed ID: 35769948
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
8. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance.
Abushukair H; Ababneh O; Zaitoun S; Saeed A
Cancer Treat Res Commun; 2022; 33():100643. PubMed ID: 36175334
[TBL] [Abstract][Full Text] [Related]
9. FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin.
Pol JG; Le Naour J; Kroemer G
Oncoimmunology; 2020; 9(1):1755214. PubMed ID: 32363127
[TBL] [Abstract][Full Text] [Related]
10. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.
Pan H; Liu P; Kroemer G; Kepp O
Int Rev Cell Mol Biol; 2024; 382():279-294. PubMed ID: 38225106
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
15. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
Chiaravalli M; Spring A; Agostini A; Piro G; Carbone C; Tortora G
Cells; 2022 Sep; 11(19):. PubMed ID: 36230995
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Fang X; Zhong C; Weng S; Hu H; Wang J; Xiao Q; Wang J; Sun L; Xu D; Liao X; Dong C; Zhang S; Li J; Ding K; Yuan Y
BMC Cancer; 2023 Jul; 23(1):676. PubMed ID: 37464378
[TBL] [Abstract][Full Text] [Related]
19. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
